Multidimensional scaling analysis identifies pathological and prognostically relevant profiles of circulating T‐cells in chronic lymphocytic leukemia
- 18 April 2014
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 135 (10) , 2370-2379
Abstract
Antitumor immunity in chronic lymphocytic leukemia (CLL) is hampered by highly dysfunctional T‐cells. Although certain T‐cell subsets have been reported to be of prognostic significance in this disease, their interplay is complex and it remains incompletely understood which of these subsets significantly drive CLL progression. Here, we determined immunological profiles of 24 circulating T‐cell subsets from 79 untreated individuals by multiparametric flow cytometry. This screening cohort included healthy donors, patients with monoclonal B‐cell lymphocytosis (MBL), Rai 0 CLL and advanced CLL. We applied multidimensional scaling analysis as rigorous and unbiased statistical tool to globally assess the composition of the circulating T‐cell environment and to generate T‐cell scores reflecting its integrity. These scores allowed clear distinction between advanced CLL and healthy controls, whereas both MBL and Rai 0 CLL showed intermediate scores mirroring the biological continuum of CLL and its precursor stages. T‐cell stimulation and suppression assays as well as longitudinal T‐cell profiling showed an increasingly suppressive regulatory function initiating at the MBL stage. Effector function was impaired only after transition to CLL and partially recovered after chemoimmunotherapy. In an independent validation cohort of 52 untreated CLL cases, aberrant T‐cell profiles were significantly associated with shorter time to treatment independently of other prognostic parameters. Random forest modeling predicted regulatory T‐cell, gamma/delta and NKT‐cells, as well as exhaustion of the CD8+ subset as potential drivers of progression. Our data illustrate a pathological T‐cell environment in MBL that evolves toward a more and more suppressive and prognostically relevant profile across the disease stages.Keywords
Funding Information
- Hamburger Stiftung zur Förderung der Krebsbekämpfung
- Roggenbuck Stiftung
- Werner-Otto Stiftung
- Hertie Foundation
This publication has 42 references indexed in Scilit:
- A shorter time to the first treatment may be predicted by the absolute number of regulatory T‐cells in patients with Rai stage 0 chronic lymphocytic leukemiaAmerican Journal of Hematology, 2012
- A novel adoptive transfer model of chronic lymphocytic leukemia suggests a key role for T lymphocytes in the diseaseBlood, 2011
- Treatment with lenalidomide modulates T‐cell immunophenotype and cytokine production in patients with chronic lymphocytic leukemiaCancer, 2011
- Regulatory T cells predict the time to initial treatment in early stage chronic lymphocytic leukemiaCancer, 2010
- Monoclonal B-cell lymphocytosis (MBL): biology, natural history and clinical managementLeukemia, 2010
- Immune dysfunction in chronic lymphocytic leukemia T cells and lenalidomide as an immunomodulatory drugHaematologica, 2009
- Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemiaHaematologica, 2009
- Eμ- TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunctionProceedings of the National Academy of Sciences, 2009
- Multiparameter flow cytometric analysis of CD4 and CD8 T cell subsets in young and old peopleImmunity & Ageing, 2008
- Failure of B Cells of Chronic Lymphocytic Leukemia in Presenting Soluble and AlloantigensClinical Immunology and Immunopathology, 1995